Back to Search
Start Over
Identification of α2-Macroglobulin as a Master Inhibitor of Cartilage-Degrading Factors That Attenuates the Progression of Posttraumatic Osteoarthritis.
- Source :
- Arthritis & Rheumatology; Jul2014, Vol. 66 Issue 7, p1843-1853, 11p
- Publication Year :
- 2014
-
Abstract
- Objective. To determine if supplemental intraarticular α<subscript>2</subscript>-macroglobulin (α<subscript>2</subscript>M) has a chondroprotective effect in a rat model of osteoarthritis (OA). Methods. Using Western blotting, mass spectrometry, enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry, α<subscript>2</subscript>M was identified as a potential therapeutic agent through a comparison of α<subscript>2</subscript>M concentrations in serum, synovial fluid (SF), and cartilage from normal subjects and patients with OA. In cultured chondrocytes, the effects of α<subscript>2</subscript>M on interleukin-1 (IL-1)-induced cartilage catabolic enzymes were evaluated by Luminex assay and ELISA. In vivo effects on cartilage degeneration and matrix metalloproteinase 13 (MMP-13) concentration were evaluated in male rats (n =120) randomized to 1 of 4 treatments: 1) anterior cruciate ligament transection (ACLT) and saline injections, 2) ACLT and 1 IU/kg injections of α<subscript>2</subscript>M, 3) ACLT and 2 IU/kg injections of α<subscript>2</subscript>M, or 4) sham operation and saline injections. Rats were administered intraarticular injections for 6 weeks. The concentration of MMP-13 in SF lavage fluid was measured using ELISA. OA-related gene expression was quantified by real-time quantitative polymerase chain reaction. The extent of OA progression was graded by histologic examination. Results. In both normal subjects and OA patients, α<subscript>2</subscript>M levels were lower in SF as compared to serum, and in OA patients, MMP-13 levels were higher in SF than in serum. In vitro, α<subscript>2</subscript>M inhibited the induction of MMP-13 by IL-1 in a dose-dependent manner in human chondrocytes. In the rat model of ACLT OA, supplemental intraarticular injection of α<subscript>2</subscript>M reduced the concentration of MMP-13 in SF, had a favorable effect on OA-related gene expression, and attenuated OA progression. Conclusion. The plasma protease inhibitor α<subscript>2</subscript>M is not present in sufficient concentrations to inactivate the high concentrations of catabolic factors found in OA SF. Our findings suggest that supplemental intraarticular α<subscript>2</subscript>M provides chondral protection in posttraumatic OA. [ABSTRACT FROM AUTHOR]
- Subjects :
- OSTEOARTHRITIS treatment
ACADEMIC medical centers
ANALYSIS of variance
ANIMAL experimentation
ANTERIOR cruciate ligament injuries
BIOLOGICAL models
BLOOD testing
CARTILAGE diseases
ENZYME-linked immunosorbent assay
GENE expression
IMMUNOHISTOCHEMISTRY
POLYMERASE chain reaction
OSTEOARTHRITIS
RATS
RESEARCH funding
TOMOGRAPHY
WESTERN immunoblotting
REVERSE transcriptase polymerase chain reaction
DATA analysis software
DISEASE complications
DISEASE risk factors
Subjects
Details
- Language :
- English
- ISSN :
- 23265191
- Volume :
- 66
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Arthritis & Rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 103682722
- Full Text :
- https://doi.org/10.1002/art.38576